Significant Contracts - Additional Information (Detail) - USD ($)		3 Months Ended		12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2019
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Non-current deferred revenue		$ 14,012,000			$ 14,012,000	$ 12,323,000
Current deferred revenue		4,105,000			4,105,000	0
Collaboration Expense					130,250,000	110,250,000	$ 101,178,000
Defer option specified cost					110,300,000	110,300,000
Scenario Forecast [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Defer option specified cost	$ 110,300,000
A&R Vertex JDCA [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Percentage of net profits and net losses							40.00%
Revenue					200,000,000
Defer option specified cost					110,300,000	110,300,000
A&R Vertex JDCA [Member] | Scenario Forecast [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Defer option specified cost				$ 110,300,000
2019 Collaboration Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue							$ 12,000,000
March 2023 Agreements [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue					100,000,000
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone payment receivable		200,000,000			200,000,000
Research milestone payment			$ 70,000,000
Business combination, consideration transferred		200,000,000	70,000,000
Revenue					200,000		913,100,000
Collaboration Expense					130,300,000	110,300,000	101,200,000
Cost excluded from license agreement					110,300,000
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | Collaboration Target Options [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone payment receivable		410,000,000			410,000,000
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | DM1 License [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue							12,000,000
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | Exclusive License [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue							$ 900,000,000
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | A&R Vertex JDCA [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Up-front payment received					900,000,000
Percentage of net profits and net losses							60.00%
Current payment due					20,000,000
Revenue					170,000,000
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | Non-Ex License Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Up-front payment received							$ 100,000,000
Milestone payment receivable		160,000,000			160,000,000		230,000,000
Research milestone payment			$ 70,000,000
Revenue					100,000,000
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | 2015 Collaboration Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone payment receivable		395,000,000			395,000,000
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | 2019 Collaboration Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Percentage of exchange payment of research and development costs								50.00%
Maximum potential future payments					775,000,000
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | March 2023 Agreements [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue					370,000,000
Vertex Pharmaceuticals Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Non-current deferred revenue		12,300,000			12,300,000	12,300,000
Transaction price allocated to remaining performance obligations		12,300,000			12,300,000
Current deferred revenue		0			0	0
Reimbursements from research and license agreements					18,000,000	37,800,000	$ 47,400,000
Defer option specified cost		$ 20,000,000			110,300,000	$ 110,300,000
Vertex Pharmaceuticals Inc [Member] | Exclusive License [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Estimated standalone selling price for single collaboration					900,000,000
Vertex Pharmaceuticals Inc [Member] | A&R Vertex JDCA [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Up-front payment received					$ 100,000,000
Additional interest of percentage					10.00%
Vertex Pharmaceuticals Inc [Member] | March 2023 Agreements [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue					$ 70,000,000